Cooley Recognized in 11 Deals of the Year Awards in the Chinese Market
Beijing, Shanghai and Hong Kong – April 7, 2025 – Cooley was recognized for its work on 11 standout deals in the Chinese market in China Business Law Journal’s 2024 Deals of the Year awards, nearly four times the number it was honored for in 2023.
The awards list recognizes the significant deals and transactions of the past year. The firm’s 11 recognized deals were:
- Gracell Biotechnologies’ approximately $1.2 billion acquisition by AstraZeneca
- Chimagen Biosciences’ sale of CMG1A46 to GSK
- ProfoundBio’s $1.8 billion sale to Genmab
- Nuvation Bio’s acquisition of AnHeart Therapeutics
- D3 Bio’s $62 million Series A+ financing
- HighLight Capital’s (HLC’s) approximately $550 million closing of flagship HLC USD Fund IV
- Eccogene’s license agreement for ECC5004 with AstraZeneca
- Escugen Biotechnology and Foreseen Biotechnology’s license agreement for first-in-class antibody-drug conjugate with Ipsen
- FutureGen Biopharmaceutical’s license agreement with AbbVie to develop FG-M701
- Jiangsu Hengrui Pharmaceuticals’ out-license agreement of GLP-1 with Hercules CM Newco
- ImmuneOnco Biopharmaceuticals’ $2 billion licensing and collaboration agreement with Instil Bio
Cooley’s Beijing, Hong Kong and Shanghai offices represent a growing number of China’s most innovative and dynamic tech and life sciences companies, advising from formation through financings, strategic partnering activities and exits. Cooley’s seamless integration between its US, UK and Asia offices fosters its “one Cooley team” approach to client service. The teams’ in-depth subject matter knowledge and transactional prowess enable the firm to handle a raft of corporate, finance, partnering, intellectual property prosecution, regulatory, M&A, and Hong Kong and US capital markets work for international and China-based high-tech and life sciences entities engaged in growing their global business.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.